-

“Thank you, President Biden” - Owens & Minor Welcomes President Biden Strategy on COVID Response

RICHMOND, Va.--(BUSINESS WIRE)--Today, Edward Pesicka, President and CEO of Owens & Minor, a leading manufacturer of HALYARD* branded Personal Protective Equipment (PPE), welcomed the announcement from President Biden of the National Strategy for the COVID-19 Response and Pandemic Preparedness.

“Thank you, President Biden,” said Pesicka. “When Americans mask up during this crucial phase in the pandemic, we want them to reach for a Made in America mask and other PPE whenever possible. Our 15,000 teammates have been working continuously throughout the pandemic to answer the call of our country. We welcome President Biden’s thoughtful and comprehensive approach to combating this pandemic and we look forward to working with the administration.”

As one of the world’s largest vertically integrated manufacturers of a full range of healthcare PPE, and a leading distributor of medical supplies, Owens & Minor delivered more than 12 billion PPE units in the United States in 2020. Owens & Minor owns and operates an Americas-based manufacturing footprint – manufacturing our own raw materials in North Carolina and converting that raw material into N95 respirators, isolation gowns, surgical gowns, ear loop masks and other PPE in its own plants in Texas, Mexico and Honduras. Owens & Minor is also one of the very few U.S. companies to manufacture nitrile gloves at large scale within its own factory in Southeast Asia. “We offer our large-scale manufacturing expertise to the administration,” added Pesicka.

In 2020, Owens & Minor made significant investments in capital, operational efficiency, rate of operation, and expanded its workforce to ramp up production and delivery of PPE. These investments were supplemented by a Technology Investment Agreement (TIA) from the U.S. Department of Defense (DoD).

As a result of these combined efforts, Owens & Minor achieved:

  • More than 1000% increase in N95 respirator production at three Americas locations
  • Nearly 100% increase in surgical and procedure mask production
  • More than 600% increase in face shields production
  • A 300% increase in isolation gown production

Owens & Minor was also selected as one of five companies to work with the Department of Health and Human Services (HHS) to produce approximately 600 million N95 respirator masks for the U.S. market.

###

About Owens & Minor

Owens & Minor, Inc. (NYSE: OMI) is a global healthcare solutions company that incorporates product manufacturing, distribution support and innovative technology services to deliver significant and sustained value across the breadth of the industry – from acute care to patients in their home. Aligned to its Mission of Empowering Our Customers to Advance HealthcareTM, more than 15,000 global teammates serve over 4,000 healthcare industry customers. A vertically-integrated, predominantly Americas-based footprint enables Owens & Minor to reliably supply its self-manufactured surgical and PPE products. This seamless value chain integrates with a portfolio of products representing 1,200 branded suppliers. Operating continuously since 1882 from its headquarters in Richmond, Virginia, Owens & Minor has grown into a FORTUNE 500 company with operations located across North America, Asia, Europe and Latin America. For more information about Owens & Minor, visit owens-minor.com, follow @Owens_Minor on Twitter and connect on LinkedIn at www.linkedin.com/company/owens-&-minor.

Contacts

Heather Sabharwal
202-423-5879
media@owens-minor.com

Owens & Minor

NYSE:ACH
Details
Headquarters: Richmond, VA
CEO: Edward Pesicka
Employees: 6000
Organization: PUB

Release Summary
Ready to assist Biden Administration COVID strategy
Release Versions

Contacts

Heather Sabharwal
202-423-5879
media@owens-minor.com

More News From Owens & Minor

Accendra Health Announces Third Quarter 2026 Earnings Release Date and Conference Call

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the third quarter of 2026 on Thursday, November 5, 2026, after trading ends on the New York Stock Exchange.The Company will host a conference call for investors and analysts at 5:00 p.m. EST on the same day. Participants may access the call via the toll-free dial-in number at 1-833-461-5787, or the toll dial-in number at 1-585-542-9983. The conference ID access code is 829 856...

Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 6, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with the NYSE’s continued listing standards because the average closing price of the Company’s Class A Common Stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice does not result in the im...

Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today named Kenneth Gardner-Smith as the Company’s next President and Chief Executive Officer. Gardner-Smith, who has served on the Company’s Board of Directors since March 2022, is expected to assume the role early in the fourth quarter 2026. He will succeed Edward A. Pesicka, who announced his intent to retire in August. Gardner-Smith brings deep experience running large-scale patient care operations and guiding...
Back to Newsroom